Trials / Unknown
UnknownNCT02978274
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
Natural Killer Cells Reconstitution Kinetics Post T Cells Repleted Haploidentical Transplantation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution.
Detailed description
Patients with hematological malignancies suitable for allo-HSCT but without HLA-identical related or unrelated donors were candidates for the HLA-haploidentical HSCT. Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution. Peripheral blood will be collected by day15, 30, 60, 90, 180, and 1 year post transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MMF | MMF withdrawal by engraftment post haplo-SCT |
| DRUG | MMF | MMF withdrawal by 2 month post haplo-SCT |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2021-12-01
- Completion
- 2022-12-01
- First posted
- 2016-11-30
- Last updated
- 2020-10-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02978274. Inclusion in this directory is not an endorsement.